LanZhou Foci Pharmaceutical Co.,Ltd.

SZSE:002644 Stock Report

Market Cap: CN¥3.8b

LanZhou Foci PharmaceuticalLtd Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure6.5yrs
Board average tenureless than a year

Recent management updates

Recent updates

Here's Why LanZhou Foci PharmaceuticalLtd (SZSE:002644) Can Manage Its Debt Responsibly

Dec 13
Here's Why LanZhou Foci PharmaceuticalLtd (SZSE:002644) Can Manage Its Debt Responsibly

Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 01
Why LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Shaky Earnings Are Just The Beginning Of Its Problems

These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

Aug 07
These 4 Measures Indicate That LanZhou Foci PharmaceuticalLtd (SZSE:002644) Is Using Debt Reasonably Well

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

CEO

LanZhou Foci PharmaceuticalLtd has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Yingchun Wang
Deputy GM & Director5yrsCN¥379.50kno data
Guo Lin Chai
Deputy General Manager7.9yrsCN¥362.70kno data
Xiao Yun Feng
Deputy General Manager7.9yrsCN¥323.10kno data
Junhui Wang
Secretary of the Board2.2yrsCN¥277.10kno data

6.5yrs

Average Tenure

51yo

Average Age

Experienced Management: 002644's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yingchun Wang
Deputy GM & Director5yrsCN¥379.50kno data
Yunjie Wang
Supervisor2.7yrsno datano data
Wen Bo Su
Chairman of the Supervisory Board10.7yrsno datano data
Xinhai Wang
Director2.1yrsno datano data
Lijun Wu
Member of Supervisory Board5yrsno datano data
Wenbo Su
Supevisiorless than a yearno datano data
Xiaodong Shan
Non-Independent Directorless than a yearno datano data
Zhigang Li
Independent Directorless than a yearno datano data
Shuangxi Qian
Non-Independent Directorless than a yearno datano data
Hongwen Jia
Independent Directorless than a yearno datano data
Huayun Hu
Independent Directorless than a yearno datano data

0.4yrs

Average Tenure

49yo

Average Age

Experienced Board: 002644's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:46
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LanZhou Foci Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shanshan LiChina Merchants Securities Co. Ltd.
Ling Bo TuChina Minzu Securities
Yan WenTX Investment Consulting Co., Ltd.